On 15 de dez. de 2025, ABVX reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 4 analistas forecast an EPS of -1.52 USD, with revenue projected to reach 2.04 milhão USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Abivax SA - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Abivax SA - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Abivax SA - ADR's Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Abivax SA - ADR expected to report next?
The next earning report is scheduled for 23 de mar. de 2026.
What are the forecasts for Abivax SA - ADR's next earnings report?
Based on 4
analistas, Abivax SA - ADR is expected to report EPS of -$1.52 and revenue of $2.04M for Q4 2025.